{"url_path":"/sec/phge/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-059587-index.html","accession_number":"0001213900-26-059587","cik":"0001739174","ticker":"PHGE","issuer_name":"BiomX Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-059587-index.html","primary_entity_key":"0001739174","primary_entity_name":"BiomX Inc."},"word_count":173,"has_tables":true,"body_markdown":"** **\n\n**Item 1. Legal Proceedings.**\n\n** **\n\nWe are not currently a party to any material legal\nproceedings, other than as described below and in Note 1 to the condensed consolidated financial statements included in this Quarterly\nReport on Form 10-Q.\n\n \n\nOn December 16, 2025, our former operating subsidiary,\nBiomX Ltd. (“BiomX Israel”), commenced insolvency proceedings in [the District Court in Tel Aviv-Jaffa]. On January 25, 2026,\nthe court appointed a trustee over BiomX Israel. As a result of the appointment of the trustee and the related loss of control over BiomX\nIsrael, we deconsolidated BiomX Israel effective February 4, 2026. As of March 31, 2026, our condensed consolidated balance sheet reflects\na balance of approximately $1.3 million due to BiomX Israel, which may become subject to claims asserted by the trustee in the course\nof the insolvency proceedings. We are not able at this time to assess the likely outcome of the proceedings or to estimate the amount\nor range of any loss that may result. See Note 1 to the condensed consolidated financial statements."}